ITUA20161994A1 - Uso degli inibitori ddx3 come agenti anti-iperproliferativi - Google Patents

Uso degli inibitori ddx3 come agenti anti-iperproliferativi

Info

Publication number
ITUA20161994A1
ITUA20161994A1 ITUA2016A001994A ITUA20161994A ITUA20161994A1 IT UA20161994 A1 ITUA20161994 A1 IT UA20161994A1 IT UA2016A001994 A ITUA2016A001994 A IT UA2016A001994A IT UA20161994 A ITUA20161994 A IT UA20161994A IT UA20161994 A1 ITUA20161994 A1 IT UA20161994A1
Authority
IT
Italy
Prior art keywords
hyper
performance agents
ddx3
inhibitors
ddx3 inhibitors
Prior art date
Application number
ITUA2016A001994A
Other languages
English (en)
Inventor
Annalaura Brai
Cristina Tintori
Maurizio Botta
Original Assignee
Azienda Ospedaliera Univ Senese
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Azienda Ospedaliera Univ Senese filed Critical Azienda Ospedaliera Univ Senese
Priority to ITUA2016A001994A priority Critical patent/ITUA20161994A1/it
Priority to CN201780026194.4A priority patent/CN109069484A/zh
Priority to AU2017236095A priority patent/AU2017236095A1/en
Priority to US16/086,791 priority patent/US11000512B2/en
Priority to PCT/EP2017/057010 priority patent/WO2017162834A1/en
Priority to EP17713011.9A priority patent/EP3432881B1/en
Priority to JP2018549791A priority patent/JP7073269B2/ja
Publication of ITUA20161994A1 publication Critical patent/ITUA20161994A1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
ITUA2016A001994A 2016-03-24 2016-03-24 Uso degli inibitori ddx3 come agenti anti-iperproliferativi ITUA20161994A1 (it)

Priority Applications (7)

Application Number Priority Date Filing Date Title
ITUA2016A001994A ITUA20161994A1 (it) 2016-03-24 2016-03-24 Uso degli inibitori ddx3 come agenti anti-iperproliferativi
CN201780026194.4A CN109069484A (zh) 2016-03-24 2017-03-23 Ddx3抑制剂作为抗增殖剂的用途
AU2017236095A AU2017236095A1 (en) 2016-03-24 2017-03-23 Use of DDX3 inhibitors as antiproliferative agents
US16/086,791 US11000512B2 (en) 2016-03-24 2017-03-23 Use of DDX3 inhibitors as antiproliferative agents
PCT/EP2017/057010 WO2017162834A1 (en) 2016-03-24 2017-03-23 Use of ddx3 inhibitors as antiproliferative agents
EP17713011.9A EP3432881B1 (en) 2016-03-24 2017-03-23 Use of ddx3 inhibitors as antiproliferative agents
JP2018549791A JP7073269B2 (ja) 2016-03-24 2017-03-23 抗増殖剤としてのｄｄｘ３阻害剤の使用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITUA2016A001994A ITUA20161994A1 (it) 2016-03-24 2016-03-24 Uso degli inibitori ddx3 come agenti anti-iperproliferativi

Publications (1)

Publication Number Publication Date
ITUA20161994A1 true ITUA20161994A1 (it) 2017-09-24

Family

ID=56235887

Family Applications (1)

Application Number Title Priority Date Filing Date
ITUA2016A001994A ITUA20161994A1 (it) 2016-03-24 2016-03-24 Uso degli inibitori ddx3 come agenti anti-iperproliferativi

Country Status (7)

Country Link
US (1) US11000512B2 (it)
EP (1) EP3432881B1 (it)
JP (1) JP7073269B2 (it)
CN (1) CN109069484A (it)
AU (1) AU2017236095A1 (it)
IT (1) ITUA20161994A1 (it)
WO (1) WO2017162834A1 (it)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10357493B2 (en) 2017-03-10 2019-07-23 Selenity Therapeutics (Bermuda), Ltd. Metalloenzyme inhibitor compounds
WO2019028343A1 (en) * 2017-08-03 2019-02-07 Georgetown University SMALL MOLECULE INHIBITORS OF SLC25A1

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011161201A1 (en) * 2010-06-22 2011-12-29 Kancera Ab Bisarylsulfonamides useful as kinase inhibitors in the treatment of inflammation and cancer
WO2014038682A2 (en) * 2012-09-04 2014-03-13 Niigata University Cancer diagnostic and therapeutic method targeting molecules expressed in cancer stem cells
KR20140125117A (ko) * 2013-04-18 2014-10-28 한국화학연구원 카르바닐리드 유도체를 유효성분으로 포함하는 이상증식혈관 질환의 예방 또는 치료용 조성물
WO2016128541A1 (en) * 2015-02-13 2016-08-18 Azienda Ospedaliera Universitaria Senese Human helicase ddx3 inhibitors as therapeutic agents

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4621A (en) 1846-07-07 stkong
US23A (en) 1836-09-08 Ftjkitace for warming buildings
FR2521565B1 (fr) 1982-02-17 1985-07-05 Dior Sa Parfums Christian Melange pulverulent de constituants lipidiques et de constituants hydrophobes, procede pour le preparer, phases lamellaires lipidiques hydratees et procede de fabrication, compositions pharmaceutiques ou cosmetiques comportant des phases lamellaires lipidiques hydratees
JPS61130238A (ja) * 1984-11-30 1986-06-18 Res Dev Corp Of Japan 動脈硬化巣認識モノクロナル抗体および反応試薬
US5077211A (en) 1988-07-06 1991-12-31 Applied Genetics, Inc. Purification and administration of dna repair enzymes
US20040006011A1 (en) * 1996-07-12 2004-01-08 Gour Barbara J. Peptidomimetic modulators of cell adhesion
MXPA05002493A (es) 2002-09-05 2005-05-27 Neurosearch As Derivados de diarilurea y su uso como bloqueadores del canal del cloro.
WO2005090297A1 (en) * 2004-03-19 2005-09-29 Biotie Therapies Corporation Sulphonamide derivatives
CA2575764A1 (en) * 2004-10-27 2006-05-11 Neurogen Corporation Diaryl ureas as cb1 antagonists
US9322831B2 (en) * 2008-09-23 2016-04-26 The Johns Hopkins University DDX3 as a biomarker for cancer and methods related thereto
WO2011039735A2 (en) * 2009-10-02 2011-04-07 Consiglio Nazionale Delle Ricerche Compounds with ddx3 inhibitory activity and uses thereof
WO2012142698A1 (en) * 2011-04-20 2012-10-26 Universite Laval Alkylurea derivatives active against cancer cells
US9458147B2 (en) * 2012-02-22 2016-10-04 Sanford-Burnham Medical Research Institute Sulfonamide compounds and uses as TNAP inhibitors
JP2016502987A (ja) * 2012-12-10 2016-02-01 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ＲＯＲｃモジュレーターとしてのベンジルスルホンアミド誘導体
KR101806103B1 (ko) * 2013-10-29 2017-12-07 이에이 파마 가부시키가이샤 설폰아미드 유도체 및 이의 의약 용도

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011161201A1 (en) * 2010-06-22 2011-12-29 Kancera Ab Bisarylsulfonamides useful as kinase inhibitors in the treatment of inflammation and cancer
WO2014038682A2 (en) * 2012-09-04 2014-03-13 Niigata University Cancer diagnostic and therapeutic method targeting molecules expressed in cancer stem cells
KR20140125117A (ko) * 2013-04-18 2014-10-28 한국화학연구원 카르바닐리드 유도체를 유효성분으로 포함하는 이상증식혈관 질환의 예방 또는 치료용 조성물
WO2016128541A1 (en) * 2015-02-13 2016-08-18 Azienda Ospedaliera Universitaria Senese Human helicase ddx3 inhibitors as therapeutic agents

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANNALAURA BRAI ET AL: "Human DDX3 protein is a valuable target to develop broad spectrum antiviral agents", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 113, no. 19, 26 April 2016 (2016-04-26), US, pages 5388 - 5393, XP055318193, ISSN: 0027-8424, DOI: 10.1073/pnas.1522987113 *
DATABASE WPI Week 201501, Derwent World Patents Index; AN 2014-U24010, XP002764365 *
MARCO RADI ET AL: "Discovery of the first small molecule inhibitor of human DDX3 specifically designed to target the RNA binding site: Towards the next generation HIV-1 inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, vol. 22, no. 5, 31 December 2011 (2011-12-31), pages 2094 - 2098, XP028459462, ISSN: 0960-894X, [retrieved on 20120108], DOI: 10.1016/J.BMCL.2011.12.135 *
ROBERTA FAZI ET AL: "Homology Model-Based Virtual Screening for the Identification of Human Helicase DDX3 Inhibitors", JOURNAL OF CHEMICAL INFORMATION AND MODELING, vol. 55, no. 11, 23 November 2015 (2015-11-23), US, pages 2443 - 2454, XP055263267, ISSN: 1549-9596, DOI: 10.1021/acs.jcim.5b00419 *

Also Published As

Publication number Publication date
AU2017236095A1 (en) 2018-10-18
US20190099403A1 (en) 2019-04-04
CN109069484A (zh) 2018-12-21
JP7073269B2 (ja) 2022-05-23
WO2017162834A1 (en) 2017-09-28
JP2019509313A (ja) 2019-04-04
EP3432881B1 (en) 2021-11-24
US11000512B2 (en) 2021-05-11
EP3432881A1 (en) 2019-01-30

Similar Documents

Publication Publication Date Title
DK3512850T3 (da) Inhibitorer af menin-mll-interaktionen
DK3468966T3 (da) Inhibitorer af menin-mll-interaktionen
CL2016002462A1 (es) Anticuerpos anti-ox40 y métodos de uso
BR112016015706A2 (pt) composto, uso do mesmo e composição farmacêutica
CL2018000708A1 (es) Fitasas modificadas y métodos de uso
ES2796903T8 (es) Procedimiento de uso de inmunoconjugados anti-CD79b
BR112016027722A2 (pt) compostos contendo grupo autoimulativo e seu uso
TWD178291S (zh) 軟管捲繞器（二）
EA201691610A8 (ru) Анти-jagged1 антитела и способы применения
DK3182962T3 (da) Compositions and uses of amidine derivatives
BR112016020889A2 (pt) variantes de hppd e métodos de uso
CL2018001139A1 (es) Anticuerpos anti-htra1 y métodos de uso de los mismos.
BR112016026046A2 (pt) Uso de compostos de tienotriazolodiazepina
DK3386991T3 (da) Polycykliske forbindelser som inhibitorer af bruton's tyrosinkinase
BR112016006614A2 (pt) composições de trichoderma e métodos de uso
MA51337A (fr) Inhibiteurs spiro exo-aza de l'interaction ménine-mll
IT201600100016A1 (it) Composizione di coloranti per capelli
DK3328395T3 (da) Ny brug af dextransulfat
FR3039396B1 (fr) Base de formulation cosmetique concentree
DK3137658T3 (da) Anvendelse af kendte forbindelser som d-aminosyreoxidase-inhibitorer
FR3023290B1 (fr) Derives de flavaglines
BR112017012240A2 (pt) métodos de preparação de composições contendo alcaloides e suas utilizações
BR112016021620A2 (pt) compostos e seus métodos de uso
DK3173071T3 (da) Formularing af maropitant
ITUA20161994A1 (it) Uso degli inibitori ddx3 come agenti anti-iperproliferativi